Q-omics provides the consensus-scored AGAP12P profile across patient tissues and cancer cell-line models. AGAP12P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AGAP12P is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, AGAP12P RNA expression shows 13,681 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BRCA, and UVM as cancer lineages where AGAP12P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AGAP12P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AGAP12P survival associations across molecular data types. AGAP12P RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AGAP12P RNA expression–survival associations across cancer types. High AGAP12P expression shows unfavorable associations in KIRC, UVM and BRCA, but favorable associations in STAD, BLCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for AGAP12P RNA expression.
This table summarizes AGAP12P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for AGAP12P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AGAP12P shows lower tumor expression in BRCA and LUAD and higher tumor expression in PAAD, KIRC and LIHC. The BRCA box plot shows higher AGAP12P RNA expression in normal versus tumor tissue (log2 FC = −0.252, t-test p = .004).
This table shows molecular features associated with AGAP12P in patient tissues and cancer cell lines. In patient samples, AGAP12P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, AGAP12P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in OVARY.
